Stockscreener 앱 받기
104.80
0.46%
0.48
시간 외 거래:
104.80
전일 마감가:
$104.32
열려 있는:
$104.74
하루 거래량:
311.36K
Relative Volume:
0.49
시가총액:
$5.16B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-16.05
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+1.73%
1개월 성능:
-3.33%
6개월 성능:
-0.91%
1년 성능:
+23.29%
1일 변동 폭
$103.28
$105.95
1주일 범위
$96.09
$109.88
52주 변동 폭
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
104.80 | 5.15B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Equities Analysts Issue Forecasts for AXSM Q3 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Call Transcript - MSN
XTX Topco Ltd Sells 9,794 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FY2026 EPS Estimates for AXSM Increased by Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Estimate for AXSM Earnings - MarketBeat
TD Asset Management Inc Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome outlines late-stage pipeline advancements and targets cash flow positivity amid 72% revenue growth - MSN
Federated Hermes Inc. Makes New $3.03 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for AXSM - MarketBeat
FY2026 EPS Estimates for AXSM Decreased by Cantor Fitzgerald - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for AXSM Earnings - MarketBeat
J. Safra Sarasin Holding AG Makes New $1.13 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Earnings Call Highlights Robust Growth - The Globe and Mail
Axsome Therapeutics Jumps 5% as Q2 Revenue Surpasses Projections - MSN
Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation - TipRanks
Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating - TipRanks
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $176.00 - MarketBeat
Royal Bank Of Canada Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM) - The Globe and Mail
Shareholders Have Faith in Loss-making Axsome Therapeutics (NASDAQ:AXSM) as Stock Climbs 6.1% in Past Week, Taking Three-year Gain to 146% - 富途牛牛
Axsome Therapeutics: BofA Securities Reiterates Buy Rating, Raises PT to $176. - AInvest
RBC Capital Reiterates Outperform on Axsome Therapeutics, Raises PT to $189 - AInvest
Needham & Company LLC Reaffirms Buy Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Reports Strong Q2 2025 Performance - The Globe and Mail
Axsome Therapeutics (NASDAQ:AXSM) Announces Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Axsome: Q2 Earnings Snapshot - New Haven Register
Axsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Axsome Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating - TipRanks
Analysts bullish on AbbVie, Axsome Therapeutics, and GE Healthcare Technologies Inc. - AInvest
Axsome Therapeutics, Inc. SEC 10-Q Report - TradingView
Axsome Achieves 72% Revenue Growth, Sets Sights on Cash Flow Positivity - AInvest
Axsome Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics (AXSM): Is Now the Time to Buy After a Strong Q2 Earnings Beat? - AInvest
Axsome (AXSM) Q2 Revenue Soars 72% - sharewise.com
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings - Yahoo Finance
Earnings call transcript: Axsome Therapeutics beats Q2 2025 forecasts - Investing.com
Axsome Therapeutics, Wayfair, IDEXX Laboratories - TradingView
Axsome Therapeutics Reports Narrowed Q2 Losses, Exceeds Revenue Expectations - IndexBox
Axsome Q2 2025 slides: revenue surges 72% YoY, pipeline advances on track - Investing.com UK
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Axsome Therapeutics shares 5% surge as second quarter revenue beats expectations By Investing.com - Investing.com South Africa
Axsome Therapeutics shares 5% surge as second quarter revenue beats expectations - Investing.com
Axsome Therapeutics Inc earnings beat by $0.09, revenue topped estimates - Investing.com Australia
Axsome Therapeutics Posts Strong Growth As AUVELITY Drives Sales - Finimize
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):